Morgan Stanley’s Co-Head of Healthcare Equity Capital Markets on What IO Biotechs Can Expect in 2025
What work are you leading as Managing Director, Global Capital Markets at Morgan Stanley? My focus is meeting biotech companies early and following them through their life cycle as their funding needs ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. “This is a really rational IPO ...
Large pharmaceutical companies are racing to acquire biotech platforms addressing patent cliffs and next-generation therapeutic mechanisms, with depressed valuations across these five names creating ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Several Boston-area biotechs who ...
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results